Syndax Pharmaceuticals, Inc. Overview
Pro stress-test →Syndax is a commercial-stage biopharmaceutical company advancing innovative cancer therapies, with two FDA-approved products: Revuforj (revumenib), a menin inhibitor, and Niktimvo (axatilimab-csfr), a monoclonal antibody targeting the CSF-1 receptor. The company achieved its third FDA approval and successfully launched these two medicines in 2025, advancing toward profitability.
Strategic Profile
Pro stress-test →Syndax generated over $275 million in 2025 sales across its two lead products, demonstrating strong commercial execution and market penetration. The company initiated REVEAL-ND, a Phase 3 trial of revumenib in newly diagnosed NPM1m AML patients, designed to support both accelerated and full FDA approval.
Competitive Landscape
Pro stress-test →Syndax's Revuforj is a menin inhibitor for relapsed/refractory acute leukemia, while the company is expanding revumenib across multiple AML subtypes and exploring metastatic colorectal cancer. Revuforj appears to be the first approved menin inhibitor with dominant market position in its mechanism class. Niktimvo competes in the CSF-1R blocking antibody space for chronic GVHD.
Industry Context
Syndax Pharmaceuticals, Inc. operates in Biopharmaceutical - Oncology.
Key facts
Founded: 2005 · Headquarters: New York, New York · Employees: N/A · Revenue: $172.4M (FY2025) · Market cap: N/A